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Abstract
Background: Lung cancer, especially non-small cell lung cancer (NSCLC) is the major cause of cancer-related deaths in the
United States. The aggressiveness of NSCLC has been shown to be associated with the acquisition of epithelial-to-
mesenchymal transition (EMT). The acquisition of EMT phenotype induced by TGF-b1in several cancer cells has been
implicated in tumor aggressiveness and resistance to conventional therapeutics; however, the molecular mechanism of EMT
and tumor aggressiveness in NSCLC remains unknown.
Methodology/Principal Findings: In this study we found for the first time that the induction of EMT by chronic exposure of
A549 NSCLC cells to TGF-b1 (A549-M cells) led to the up-regulation of sonic hedgehog (Shh) both at the mRNA and protein
levels causing activation of hedgehog signaling. These results were also reproduced in another NSCLC cell line (H2030).
Induction of EMT was found to be consistent with aggressive characteristics such as increased clonogenic growth, cell
motility and invasion. The aggressiveness of these cells was attenuated by the treatment of A549-M cells with
pharmacological inhibitors of Hh signaling in addition to Shh knock-down by siRNA. The inhibition of Hh signaling by
pharmacological inhibitors led to the reversal of EMT phenotype as confirmed by the reduction of mesenchymal markers
such as ZEB1 and Fibronectin, and induction of epithelial marker E-cadherin. In addition, knock-down of Shh by siRNA
significantly attenuated EMT induction by TGF-b1.
Conclusions/Significance: Our results show for the first time the transcriptional up-regulation of Shh by TGF-b1, which is
mechanistically associated with TGF-b1 induced EMT phenotype and aggressive behavior of NSCLC cells. Thus the inhibitors
of Shh signaling could be useful for the reversal of EMT phenotype, which would inhibit the metastatic potential of NSCLC
cells and also make these tumors more sensitive to conventional therapeutics.
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Introduction
An estimated 1.35 million individuals were diagnosed with lung
cancer worldwide in 2009. Lung cancer is the most common cause
of cancer related mortality in the United States, with more than
160,000 deaths per year and 85% of all lung cancers are non-small
cell lung cancer (NSCLC) [1]. Greater than 70% of NSCLC
patients, at present, shows metastases to the regional lymph nodes
or to distant sites [2]. While, systemic therapy plays a major role in
the management of most NSCLC patients, the benefits of systemic
therapy are modest. The median survival of NSCLC patients with
distant metastases ranges from 9-12 months, with median
progression free survival (PFS) of only 3.5 to 5.5 months.
Therefore, there is an urgent need to develop novel therapies
based on newer understanding of the molecular mechanisms and
pathways that participate in lung carcinogenesis for better and
improved treatment of patients diagnosed with NSCLC.
Emerging evidence suggests that the acquisition of epithelial-to-
mesenchymal transition (EMT) phenotype could be induced by
Transforming Growth Factor-b (TGF-b) especially TGF-b1
among other factors, resulting in tumor invasiveness, and these
EMT-type cells have been classified as cancer stem-like cells in
recent studies [3]. The importance of EMT process have been
established in embryonic development [4]. Lately, EMT has also
been found to play a critical role in tumor invasion, metastatic
dissemination and the acquisition of resistance to conventional
therapies [5–12]. Moreover, EMT phenotype in cancers has been
associated with poor clinical outcome in multiple cancer types
including NSCLC, yet the molecular mechanisms underlying the
induction of EMT by TGF-b1 remain ill-defined especially for
NSCLC [13–17].
Since the acquisition of an EMT phenotype has emerged as
an important mediator of cancer progression, cancer metastases
and resistance to both chemotherapy and targeted drugs such as
EGFR inhibitors, thus further mechanistic studies to ascertain
the role of TGF-b1- induced EMT are warranted. The clinical
relevance of EMT and drug insensitivity comes from recent
studies showing an association between epithelial markers and
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that EMT-type cells are resistant to erlotinib, however the role
of signaling molecules in mediating the induction of EMT by
TGF-b1 is lacking. Among the various molecular pathways, the
Hedgehog (Hh) signaling pathway has emerged as an important
mediator of carcinogenesis and cancer metastases [20,21].
Studies have shown that the Hh signaling pathway, a pathway
normally active in human embryogenesis and tissue repair, is
also active in many cancers including NSCLC [22–25]. Hh
inhibitors are now being tested in preclinical and clinical settings
based on findings that the inhibition of Hh signaling could
inhibit cell growth, invasion and metastasis of cancer cells [26–
28]. The Hh signaling pathway is comprised of the ligand sonic,
indian, and desert hedghog (Shh, Ihh, Dhh, respectivly), and the
cell surface molecules Patched (PTCH) and Smoothened (SMO).
In the absence of an Hh ligand, PTCH causes suppression of
SMO [29,30]; however, upon ligand binding to PTCH, SMO
protein translocates into the primary cilium, and leads to the
activation of transcription factor GLI1, which then translocates
to the nucleus, leading to the expression of Hh target genes
[29,30]. GLI1-mediated expression of genes is involved in cell
growth and differentiation [29], and thus the activation of Hh
signaling is believed to play an important role in tumor cell
invasion and metastasis.
Based on the above findings and the lack of mechanistic
studies in establishing the role of TGF-b1-induced activation of
Hh signaling with respect to the acquisition of EMT and tumor
cell aggressiveness, we used NSCLC cells as a preclinical model
for the current study. Here we show for the first time that
chronic exposure of A549 cells (NSCLC cells) to TGF-b1l e dt o
the acquisition of EMT phenotype with concomitant up-
regulation of sonic hedgehog (Shh) both at the mRNA and at
the protein levels, which is consistent with findings in another
NSCLC cell line (H2030). The up-regulation of sonic hedgehog
was consistent with increased cell motility, invasion, and tumor
cell aggressiveness. In addition, we found that this process could
be attenuated by Shh siRNA as well as by chemical inhibitors of
Hh signaling such as cyclopamine and GDC-0449. Moreover,
we found that the inhibition of Hh signaling by pharmacolog-
ical inhibitors led to the reversal of EMT phenotype as
confirmed by the reduction of mesenchymal markers such as
ZEB1 and Fibronectin, and induction of epithelial marker E-
cadherin, suggesting that the acquisition of EMT phenotype by
TGF-b1 in NSCLC cells is mechanistically mediated by
the activation of Shh signaling because the knock-down of
Shh by Shh specific siRNA attenuated TGF-b1-induced EMT
phenotype.
Results
Induction of epithelial-to-mesenchymal transition (EMT)
in A549 NSCLC cells by chronic exposure to TGF-b1
It has been reported that A549 cells undergoes EMT
phenotypic changes upon exposure to TGF-b1 [13,14]. This was
seen as trans-differentiation, especially because the exposure was
done for a short period of time (48–72 hours). In an attempt to
recapitulate the in vivo situation where cells are chronically exposed
to TGF-b1 in the tumor microenvironment, we exposed A549
cells to TGF-b1 up to three weeks. After 21 days of exposure to
TGF-b1, A549 cells morphology was found to be completely
changed to a mesenchymal phenotype (we termed this cells as
A549-M cells), with an elongated and disseminated appearance
(Fig. 1A). To confirm the mesenchymal phenotype, we assessed the
expression of molecular markers of EMT such as ZEB1 mRNA,
which has been reported earlier to serve as a mesenchymal marker
[31,32], and we found that ZEB1 was up-regulated, while the
expression of E-cadherin mRNA, an epithelial marker, was down-
regulated (Fig. 1B). Fibronectin protein, a mesenchymal marker
[17], was also found to be highly up-regulated in A549-M cells
(Fig. 1C).
A549-M cells showed significant increase in cell
migration and invasive characteristics compared to the
A549 parental cells
Previous studies have shown that tumor cells with EMT
phenotype are more motile [14,17,32,33]. In order to further
characterize A549-M cells, we performed a wound healing assay
which showed increased cell migration of A549-M cells compared
to parental cells (Fig. 2A). Moreover, we also found that A549-M
cells are more invasive as documented by increased invasion as
documented by matrigel-coated chamber assay (Fig. 2B), and
A549-M cells also acquired more tumorigenic phenotype as
documented by increased clonogenic growth (Fig. 2C).
A549-M cells showed up-regulation of sonic hedgehog
mRNA, and protein expression
In order to assess the mechanism by which chronic TGF-b1
treatment induced EMT and tumor cell aggressiveness, we
focused our investigation on Hh signaling because it has
been implicated in EMT induction, metastasis and invasion
[20–24,26,34,34–37]. Interestingly, we found a dramatic increase
in the expression of Hh pathway ligand Shh both at the mRNA
and protein levels in A549-M cells whereas the parental A549
cells showed undetectable levels of Shh mRNA (Fig. 3A and
Fig. 3B), which is consistent with published data showing that
A549 parental cells contains undetectable levels of Shh expression
[35]. In order to further confirm our findings documenting up-
regulation of Shh by TGF-b1 treatment, and the induction of
EMT in A549 NSCLC cell lines, we treated another NSCLC cell
line (H2030 cells) with TGF-b1 for two weeks, and we found a
significant increase in the expression of Shh mRNA, which was
consistent with the induction of EMT marker ZEB1 and down-
regulation of epithelial marker E-cadherin (Fig. 4A). These results
suggest that TGF-b1 induced EMT is mediated by the
transcriptional activation of Shh, which is the first such report
in the literature.
Interestingly, GLI1 levels in both A549-M and parental cells
were higher compared to normal human bronchial epithelial cells
(NHBE cells) although the expression of GLI1 was much more
increased in A549-M cells (Fig. 3C and Fig. 3D). The high levels
of Hh target gene GLI1 in both A549-M and A549 cells was
observed despite the undetectable levels of Shh in A549 parental
cells, which suggests that the expression of GLI1 could be ligand-
independent in the parental A549 cells. Moreover, since Shh
protein expression in A549-M cells appears to induce the GLI1
expression by an autocrine process, we further investigated this
possibility using NIH-3T3 cells cultured with condition-media of
A549-M cells. NIH-3T3 cells express Hh signaling receptor and
transcription factor GLI1, and our data confirmed showing
increased Hh signaling consistent with increased expression of
GLI1 (Fig. 3E) in NIH-3T3 cells cultured with A549-M condition
media. These results clearly show that A549-M cells secrete active
Shh which can then activate Hh signaling in NIH 3T3 cells,
resulting in the activation of GLI1. We further investigated the
possibility whether Shh up-regulation directly mediates EMT
induction by TGF-b1 or not. We found that knock-down of Shh
by siRNA significantly attenuated TGF-b1 induced EMT, which
TGF-b1 Up-Regulate Sonic Hedgehog Protein
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below. A549 cells transfected with Shh siRNA 24 hrs prior to
treatment with TGF-b1 for 48 hrs (A549-siShh) maintained
epithelial morphology, while scrambled siRNA (A549-si-ve)
showed transformation to mesenchymal morphology (Fig. 4B left
panel). Likewise, A549-si-ve showed more EMT induction
compared to A549-siShh following re-transfection with Shh
siRNA and treatment with TGF-b1 [Total six days of Shh
siRNA transfection and five days after TGF-b1t r e a t m e n t ;d e t a i l s
under figure legend (Fig. 4B right panel)]. The Shh siRNA
trasfection resulted in significant knock-down of Shh expression
as shown by qRT-PCR (Fig. 4C). We found significant
attenuation in the induction of EMT by TGF-b1t r e a t m e n ti n
A549 cells with Shh knock-down (A549-siShh cells) as confirmed
by qRT-PCR. A549-si-ve cells showed down-regulation of
epithelial marker, E-cadherin consistent with significant induction
in the expression of ZEB1 as expected (Fig. 4D, 48 hrs TGF-b1)
whereas TGF-b1 failed to show effect on these markers in A549-
siShh cells. Moreover, we found further attenuation in EMT
induction following second round of Shh siRNA transfection and
TGF-b1 treatment. A549-si-ve cells showed a significant increase
in ZEB1 expression consistent with significant down-regulation of
E-cadherin (Fig. 4D, 5 days TGF-b1) whereas TGF-b1 failed to
show effect on these markers in A549-siShh cells. These results
demonstrated for the first time that Shh up-regulation by TGF-
b1 is mechanistically linked with TGF-b1 induced EMT in
NSCLC cells.
Up-regulation of Shh in A549-M contributes to EMT-
induced tumor cell migration and metastatic
characteristics
Next, we investigated the role of increased expression of Shh in
aggressive behavior such as migratory and metastatic potential of
A549-M cells. We treated A549-M cells with Shh inhibitors such
as cyclopamine and GDC-0449 and assessed their migration and
invasion characteristics. Both cyclopamine and GDC-0449
significantly reduced cell migration and invasive capacity of
A549-M cells (Fig. 5A–C and Fig. S1). Moreover, the treatment of
A549-M cells by either cyclopamine (data not shown) or GDC-
0449 showed partial reversal, where we observed incomplete
attenuation of EMT phenotype, as documented by the reduced
expression of fibronectin and ZEB1, and increased expression of
epithelial marker E-cadherin (Fig. 5D and E).
In order to further confirm the role of the induced expression of
Shh by TGF-b1 in A549-M cells and its mechanistic association
with increased cell migration, invasion and tumorigenesis, we
knock-down the expression of Shh protein in A549-M cells by
Shh-specific siRNA, and further assessed the transfection efficien-
cy, which showed robust transfection efficiency (Fig. 6A). The
knock-down of Shh protein in A549-M cells showed significant
reduction in cell migration, invasion, and tumorigenic character-
istics (Fig. 6B–D). The data clearly suggests the reversal of EMT
morphology by the knock-down of Shh protein in A549-M cells
(Fig. 6B inset). These data further confirmed that the inhibition in
cell migration, invasion, and tumorigenic potential of A549-M
Figure 1. Induction of epithelial to mesenchymal transition (EMT) in A549 cells by chronic exposure to TGF-b1: TGF-b1 was added to
A549 cells in culture media and maintained for 21 days with changing medium every third day with freshly added TGF-b1. A) Phase contrast objective
microscopic pictures at 106 magnification. A549 cells morphology changed to mesenchymal phenotype (A549-M cells). Cell shape appears
elongated and non-polarized. B) qRT-PCR of A549 and A549-M cells. A549-M cells showed a lower E-cadherin ‘‘epithelial marker,’’ and a higher ZEB1
‘‘EMT marker’’, at the mRNA levels. Delta-delta-CT was calculated, considering GAPDH as internal control and A549 parental as reference control.
C) Western blot analysis where A549-M cells showed up-regulation of fibronectin ‘‘mesenchymal’’ marker compared to A549 parental cells.
doi:10.1371/journal.pone.0016068.g001
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mediated autocrine signaling.
Down-regulation of Shh autocrine signaling in additional
NSCLC cell lines led to the reduction in tumor cell
migration, invasion, and tumorigenic characteristics
In order to further investigate whether the inhibition of Shh
autocrine signaling leads to the reduction in cell migration, inva-
sion, and tumorigenesis in other NSCLC cell lines that expresses
Shh, we chose H1299 and H1650 cell lines, both of which were
derived from lung metastasis of NSCLC patients. Both cell lines
have been shown to be resistant to chemotherapy and targeted
therapy (e.g. Erlotinib) [17,38,39]. Our results confirmed that both
the cell lines expressed Shh as documented by qRT-PCR and
Western blot analysis (Fig. 7A). Treatment of H1650 cells with
Shh inhibitors GDC-0449 showed decreased cell migration,
invasion and tumorigenic characteristics (Fig. 7B–C andFig. S1),
Figure 2. A549-M cells shows significant increase in migration, invasive, and tumorigenic characteristics compared to A549
parental cells: TGF-b1-induced EMT phenotypic cells (A549-M cells) were generated as discussed under ‘‘Materials and Methods’’ section. A: showed
wound healing assay results with its quantitative analysis. A549-M cells showed much higher motility compared to A549 parental cells. B and C
showing the results of matrigel-coated membrane, and colony formation assays, respectively with its quantitative analysis. Significant increase was
observed in the invasion and clonogenicity of A549-M cells compared to parental A549 cells. (* = p,0.05).
doi:10.1371/journal.pone.0016068.g002
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role Shh in EMT phenotype. It is important to note that the
treatment of H1650 cells with GDC-0449 led to the partial
reversal of the EMT phenotype as documented by the reduced
expression of fibronectin and ZEB1, and the increased expression
of E-cadherin (Fig. 7D and E), which is consistent with the data in
A549-M cells as presented under Fig. 5D and E. Moreover, these
results are also consistent with the knock-down of Shh by Shh-
specific siRNA in H1650 cells with robust transfection efficiency
(Fig. 8A), and resulting in a significant reduction in cell migration
and invasion (Fig. 8B and Fig. 8C). In addition, the treatment of
H1299 cells with GDC-0449 or cyclopamine led to a significant
reduction in invasion and tumorigenic behavior as assessed by
clonogenic growth (Fig. S2A-B and Fig. S1). The treatment of
H1299 cells with GDC-0449 also led to the partial reversal of the
EMT phenotype as documented by reduced expression of
fibronectin and ZEB1, and the increased expression of E-cadherin
(Fig. S2C-D).
Discussion
Previous studies have shown that the treatment of NSCLC cells
(A549 cells) with TGF-b1 could induce EMT phenotype
[13,14,16], a process that was originally reported to be involved
in embryogenesis and gastrulation [4,9,40]. The induction of
EMT in cancer cells confers these cells with the ability to become
more motile and invasive with increased tumorigenic potential
[4,9,11,17,18,32,33,41]. Furthermore, the EMT phenotype
appears to be involved in resistance to therapeutic agents. Thus,
reversal of EMT by novel approaches may provide a tool by
which one could enhance the effects of conventional therapeutic
agents.
Figure 3. A549-M cells showed up-regulation of sonic hedgehog (Shh) and GLI expression both at the mRNA and protein levels: A
and B showing qRT-PCR and Western blot results, respectively for the expression of Shh whereas C and D represent the expression status of GLI at the
mRNA and protein levels, respectively in A549-M cells compared to parental A549 cells. E represent Western blot data of GLI1 expression in NIH-3T3
cell after culturing with A549-M-derived conditioned media showing higher levels of GLI1 expression. (* = p,0.05).
doi:10.1371/journal.pone.0016068.g003
TGF-b1 Up-Regulate Sonic Hedgehog Protein
PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e16068Figure 4. Shh up-regulation is concomitant with TGF-b1-induced EMT in NSCLC cell lines. The up-regulation of Shh contributes to the
EMT induction through TGF-b1. (A) H2030 cell line was treated with TGF-b1 (5 ng/ml) for two weeks, and the media was changed every three days.
The qRT-PCR data showed induced expression of EMT marker ZEB1 mRNA, and reduced expression of epithelial marker E-cadherin mRNA, which was
consistent with up-regulation of Shh mRNA similar to those observed in A549 cells exposed to TGF-b1. (B, C and D) A549 cells was transfected with
Shh siRNA (A549-siShh) or scrambled siRNA (A549-si-ve) for 24 hrs prior to treatment with TGF-b1 (5 ng/ml) for 48 hrs, then the cells where collected
for assays or re-transfected for the second time with siRNA or scrambled siRNA for 24 hrs (total 6days after siShh transfection) prior to the second
time treatment with TGF-b1 (5 ng/ml) for another 48 hrs (total 5days of TGF-b1 treatment). (B) Upper panel shows transfection efficiency, and lower
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EMT phenotypic changes (A549-M and H2030-M cells) after
chronic exposure to TGF-b1, which was consistent with decreased
expression of epithelial marker concomitant with increased
expression of mesenchymal markers (Fig. 1A–C; Fig. 4A). In order
to further characterize these cells, we assessed the ability of A549-M
cells compared to A549 parental cells for cell migration, invasion
and tumorigenic potential. Our data showed increased ability of
A549-M cells for cell migration, invasion and tumorigenic potential
compared to parental A549 cells (Fig. 2A–C). Interestingly, we also
found that A549-M and H2030 cells showed high expression of Shh
both at the mRNA and protein levels compared to parental cells
(undetectable levels of Shhexpression) (Fig. 3A–B; Fig.4A). The up-
regulation of Shh expression in A549-M cells is the first of its kind,
which was also consistent with increased expression of GLI1
transcription factor, a downstream target gene of Hh signaling
pathway (Fig. 3C–D) although the basal level of GLI1 expression
was found to be high in the parental A549 cells. These results
suggest that Hh signaling could be very active through non-
canonical pathway (ligand-independence) in these cells. Our novel
finding is very interesting not only because it connects two very
important molecules ofthe developmentalpathway suchasTGF-b1
and Shh [42,43] to tumor aggressiveness, but it is also consistent
with published reports showing the role of EMT in tumor
aggressiveness and metastasis [22,25,26,31,44–46]. However, no
studies have shown the direct up-regulation of Hh ligand Shh
mRNA and protein by TGF-b1 as documented in our current
report although Shh has been reported to activate TGF-b family
signaling through the ALK5-Smad 3 pathway in gastric cancer cells
[21]. Moreover, it has been reported that TGF-b1 can induce GLI2
activation through Smad3 in pancreatic adenocarcinoma cell lines
[47], and these published results suggest that there may exist a feed-
back loop connectingTGF-b1 withShhactivation. Our finding also
suggest that Hh signaling pathway reactivation in cancer epithelial
cells within the tumor microenvironment could lead to the
acquisition of aggressive phenotype of cancer cells within a tumor.
Although the mechanisms by which TGF-b1 can induce Hh
ligand expression needs further investigation, our data clearly
suggest that the activation of Shh signaling by TGF-b1 leads to
increased tumor cell migration, invasion and tumorigenic potential
of A549-M cells as documented by our mechanistic experiments
using knock-down approach and by using chemical inhibitors of
Shh signaling (Fig. 5A-C). Our results also suggest that the
maintenance of EMT phenotype in A549-M cells may be related
to the sustained activation of Hh. These results are also consistent
with two other NSCLC cell lines that were derived from patients
metastasis (H1650, H1299), and these two cell lines showed high
basal levels of Shh expression, suggesting that lung metastatic cells
have the ability to undergo EMT consistent with higher expression
of Shh in vivo. Interestingly, the inhibition of TGF-b1-induced Shh
signaling by pharmacological inhibitors or by siRNA decreased
the ability of A549-M cells to migrate, invade and forming colony,
and these results are consistent with previous reports showing that
the activation of Shh signaling could increase invasion and
metastasis [21,23–26,37,44,48].
We have also shown that the conditioned medium from A549-
M cells has the ability to activate Shh downstream signaling in
NIH 3T3 cells, which suggests that TGF-b1-induced EMT is
mediated by the activation of Shh through both autocrine, paracr-
ine or juxtacrine mechanisms although further mechanistic studies
are warranted. Our results further showed the importance of Shh
in EMT phenomenon, wherein inhibition of Shh signaling by
GDC-0449 was able to down-regulate mesenchymal markers such
as ZEB1 and fibronectin, which was consistent with up-regulation
of epithelial marker such as E-cadherin (Fig. 5D and E and Fig. 7D
and E). These results suggest that the attenuation of Shh signaling
could reverse the EMT phenotype to mesenchymal-to-epithelial
transition (MET) as shown in Fig. 6B (inset) where cells look more
annular after Shh siRNA transfection, resulting in decreased cell
migration, invasion and tumorigenic potential, which is consistent
with the suggestion made by Feldmann et. al. [26]. More
importantly, our data show for the first time that TGF-b1 induced
EMT is mediated through up-regulation of Shh because knock-
down of Shh by Shh specific siRNA significantly attenuated EMT
induction by TGF-b1 treatment (Fig. 4B, C and D).
Clinically, NSCLC tumor tissues show higher levels of GLI1
expression compared to NSCLC cell lines [44], suggesting that the
EMT phenotype with activated Shh signaling may be context-
dependent such as what can be found in the tumor microenvi-
ronment where the tumor cells are chronically exposed to many
factors including TGF-b1. This contention is partly supported by
our data using four different NSCLC cell lines with epithelial vs.
mesenchymal phenotype, and also suggested by a recently
published report showing that chronic exposure to TGF-b1i n
the tumor microenvironment may lead to the acquisition of EMT
phenotype, which further leads to increased cell motility and
invasiveness, resulting in tumor metastasis [46].
Based on existing evidence in the literature and our current
data, we propose a model where epithelial tumor cells could be
chronically exposed to TGF-b1 excreted by either stromal cells,
immune cells or the tumor cells within the tumor microenviron-
ment, resulting in the up-regulation of Shh both at the mRNA and
at the protein levels and consequently causes activation of Hh
signaling and the acquisition of EMT phenotype, which is
responsible for tumor cell aggressiveness and metastasis (Fig. 9).
Therefore, the inhibition of Shh signaling could be a useful
approach for reducing tumor aggressiveness in NSCLC, and as
such, the reversal of EMT could also be useful for re-sensitization
of drug-resistant NSCLC to conventional therapeutics, which
would likely contribute to the improved survival of patients who
rightfully deserve better treatment outcomes.
Materials and Methods
Cell Lines
The human lung adenocarcinoma cell lines, A549, H2030,
H1299, H1650, and mouse fibroblast NIH-3T3 cells were
purchased from the American Type Culture Collection (Manassas,
VA) and maintained according to the American Type Culture
Collection’s instructions. The normal lung epithelial cell line
(NHBE cells) was purchased from Lonza. NHBE cells where
maintained and cultured according to Lonza’s instructions. All the
cell lines have been tested and authenticated using the Karmanos
Cancer Center, Wayne State University’s core facility (Applied
panel shows cellular morphology following treatments. A549-siShh maintained epithelial morphology after treatment with TGF-b1 at both time
points as shown in left and right panels, respectively. (C) qRT-PCR expression of Shh mRNA showing significant down-regulation following Shh siRNA
transfection (D) qRT-PCR expression of ZEB1 and E-cadherin mRNA. A549-si-ve cells showed down-regulation of epithelial marker, E-cadherin
consistent with significant induction in the expression of ZEB1 as expected whereas TGF-b1 failed to show any effect on these markers in A549-siShh
cells.
doi:10.1371/journal.pone.0016068.g004
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March 13, 2009, and these authenticated cells were frozen for
subsequent use. The method used for testing was short tandem
repeat profiling using the PowerPlex 16 System from Promega.
A549 cells were treated with TGF-b1 (5 ng/ml) for 21 days before
experiments were conducted. Cells were treated with GDC-0449
(20 nM) or Cyclopamine (2 mM) for 72 hours, before conducting
assays.
Reagents and antibodies
Anti-Shh N-terminal peptide antibody and recombinant human
TGF-b1 protein was purchased from R&D Systems (Minneapolis,
MN). Cyclopamine was purchased from Sigma (San Louis, MO)
and diluted in dimethyl sulfoxide (control vehicle). GDC-0449
(20 nM) was obtained from Genentech. Rabbit anti-GLI1 was
purchased from Abcam. Rabbit anti-fibronectin was obtained
from Santa Cruz biotechnology (CA, USA). Antibodies to
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were pur-
chased from Affinity BioReagents (Golden, CO.). Mouse anti-b-
actin was obtained from Sigma (St. Louis, MO). b-tubulin rabbit
mAb was obtained from cell signaling (Danvers, MA).
Cell proliferation assay
Cells were treated with TGF-b1 for 21 days, Hh inhibitor for
three-72 hour treatments, or knock-down with siRNA specific for
Shh (si-Shh) for 48 hours. Prior to treatment, cells were seeded
at 5610
3 cells per 100 ml of culture medium per well in 96-well
plates. The number of viable cells was assessed in triplicate wells
using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay (Sigma) according to the manufacturer’s
instructions. All assays were done in triplicates, and each
experiment was repeated, at least, three times independently.
Data reported here is one representative experiment.
Wound healing assay
Cells were treated with TGF-b1 for 21 days, Hh inhibitor for
three-72 hour treatments, or knock-down with siRNA specific for
Shh (si-Shh) for 48 hours. Prior to treatment, cells were seeded at
1610
6 cellsperwellina 6-wellplates.Upon .90%confluence,cells
were scraped across the cell monolayer using a plastic 200 ml tip.
Photomicrographs were taken with Phase contrast objective
microscope 46magnification,atzerotime pointandafter24 hours.
The measured ratio of the remaining wound area relative to the
initial wound area was Quantified and reported. Quantification of
the wound area using the NIH Image-J program was performed,
and the results are expressed as the percentage of wound area
change. Experiment was repeated at least three times, indepen-
dently. Data reported here is one representative experiment.
Matrigel invasion assay
Cells were treated with TGF-b1 for 21 days, Hh inhibitor for
three-72 hour treatments, or knock-down with siRNA specific for
Shh (si-Shh) for 48 hours. Following seeding cells at 5610
4 cells/
well, invading cells at the bottom of the membrane and media in
the lower chamber were detected by pre-labeled with DiIC12 (3)
Fluorescent Dye or by post-staining using immune-staining Diff-
Quick
TM staining kit after removal of noninvasive cells. Cells were
seeded in the upper chamber of a 24-insert with serum-free
medium. Upper chambers coated with Matrigel (fluoro-block
insert and MATRIGEL
TM Invasion Chamber; BD Biosciences,
USA). Lower chamber contained 10% FBS plus regular media.
After 24 h of incubation, invading cells were examined by using a
fluorescence microscope and photographed. The transfection
efficiency was photographed at 10X, whereas invading cells was
photographed at 46magnification. TECAN Ultra imaging system
was used to measure the fluorescence of invading cells. Immune-
stained cells were also counted under phase contrast objective
microscope (106magnification). The experiment was repeated at
least three times independently. Data reported here is one
representative experiment.
Small interfering RNA (siRNA) transfection
Small interfering RNA (siRNA) specific for Shh (SHH Stealth
RNAi
TM siRNA) was purchased from Invitrogen. As a non-
specific control siRNA, scrambled siRNA duplex was used which
was also purchased from Invitrogen. Transfection was done using
Lipofectamine RNAiMAX Transfection Reagent (Invitrogen)
following the manufacturer’s instruction. Experiment was repeated
at least, three times independently. Data reported here is one
representative experiment.
Western blot analysis
Whole-cell protein extraction was conducted using RIPA buffer
[50 mM Tris, 150 mM NaCl, 1%TritonX-100, 0.1% sodiumdo-
decyl sulfate and 1% Nadeoxycholate (pH 7.4)] supplemented
with protease inhibitors (1 mMphenylmethylsulfonyl fluoride,
10 mg/ml peptasin A, 10 mg/ml aprotinin and 5 mg/ml leupeptin).
Protein concentrations were then measured using Bio-Rad protein
assay kits (Bio-Rad, Hercules, CA). Next, the protein lysates were
resolved by sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS-PAGE), then transferred onto nitrocellulose mem-
branes (HybondTM-P; Amersham Biosciences, Piscataway, NJ),
blocked with phosphate-buffered saline (PBS) containing 0.2%
Tween 20 and 5% non-fat dry milk, incubated with primary
antibody and then with horseradish peroxidase-labeled secondary
antibody and developed using chemiluminiscent detection system,
and the signals were then detected using X-ray film. Experiment
was repeated at least three times independently. Data reported
here is one representative experiment.
Clonogenic assay
Cells were treated with TGF-b1 for 21 days, Hh inhibitor for
three-72 hour treatments, or knock-down with siRNA specific for
Shh (si-Shh) for 48 hours. Prior to treatment, cells were plated at a
density of 1610
3 cells in 100-mm Petri dishes. Then the cells were
incubated for 10–14 days at 37uC in a 5% CO2/5% O2/90% N2
incubator. Next, colonies were stained with 2% crystal violet and
quantified using NIH Image-J software. The experiment was
repeated at least three times independently. Data reported here is
one representative experiment.
Figure 5. Up-regulation of Shh in A549-M cells contributes to increased tumor cells migration and metastatic characteristics: A549-
M cells were treated with Shh inhibitors such as Cyclopamine (2 mM) and GDC-0449 (20 nM) and assayed for wound healing (A), invasion (B) and
clonogenic growth (C), and performed quantitative analysis showing attenuation of invasion by the treatment with Shh inhibitors. Western blot of
A549-M cells before and after treatment with GDC-0449 (20 nM) for the expression of fibronectin (D). qRT-PCR for the expression of E-cadherin and
ZEB1 mRNA in A549-M cells after treatment with GDC-0449 (20 nM) showing reversal of EMT phenotype compared to untreated A549-M cells (E).
(* = p,0.05).
doi:10.1371/journal.pone.0016068.g005
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PLoS ONE | www.plosone.org 9 January 2011 | Volume 6 | Issue 1 | e16068Figure 6. Reduction in A549-M cells motility, invasiveness, and tumorigenesis by specific knock-down of Shh using Shh-specific
siRNA: A549-M cells were transfected with Shh-specific siRNA (A): Transfection efficiency as assessed by GFP. The effect of knock-down of Shh was
assessed by cell motility (wound healing) (B), invasion (C) and clonogenic growth (D) and further quantitated as detailed under ‘‘Materials and
Methods’’ section, showing significant inhibition by Shh specific siRNA. (* = p,0.05).
doi:10.1371/journal.pone.0016068.g006
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PLoS ONE | www.plosone.org 10 January 2011 | Volume 6 | Issue 1 | e16068Figure 7. Down-regulation of Shh autocrine signaling in NSCLC cell lines led to the reduction in tumor cell migration, invasion, and
tumorigenesis: A; both H1650 and H1299 cells expresses high levels of Shh mRNA compared to NHBE cells, and both cell lines have high Shh
protein expression. B and C shows reduction in cell-invasion and the colony-forming ability of H1650 cells following treatment with Shh inhibitors
such as GDC-0449 (20 nM). (D) Western blot of H1650 cells before and after treatment with GDC-0449 (20 nM) for the expression of fibronectin. (E)
qRT-PCR for the expression of E-cadherin and ZEB1 mRNA in H1650 cells after treatment with GDC-0449 (20 nM) showing reversal of EMT compared
to untreated H1650 cells. (* = p,0.05).
doi:10.1371/journal.pone.0016068.g007
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PLoS ONE | www.plosone.org 11 January 2011 | Volume 6 | Issue 1 | e16068Quantitative Real-time PCR
Quantitative real-time RT-PCR analysis was conducted; 1 mgo f
total RNA from each sample was subjected to reverse transcription
using the High-Capacity RNA-to-cDNA Kit (Applied Biosystems)
according to the manufacturer’s protocol. Real-time PCR
reactions were then carried out in a total volume of 25 mL
reaction mixture (2 mL cDNA, 12.5 mLo f2mL SYBR Green PCR
Master Mix from Applied Biosystems, 1.5 mL of each 5 mmol/L
forward and reverse primers, and 7.5 mL distilled H2O) using a
SmartCycler II (Cepheid). The PCR program was started by
10 min at 95uC before 40 thermal cycles, each at 15 s at 95uC and
1 min at 60uC. Data were analyzed according to the comparative
Ct method. Data was normalized by glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) expression in each sample. GLI1
primers have been previously described [25]. Shh primers
(Shh-forward: GTGGCCGAGAAGACCCTA, Shh-reverse: CA-
AAGCGTTCAACTTGTCCTTA. GAPDH, ZEB1, and E-cad-
herin primers were previously described [49]. Experiment was
repeated at least, three times independently. Data reported here is
one representative experiment.
Statistical analysis
The two-tailed v2 test was performed to determine the
significance of the difference among the covariates. P values less
Figure 8. Down-regulation of Shh signaling in NSCLC cells lines (H1650 cells) leads to reduced cell motility and invasion. (A):
Transfection efficiency was assessed by GFP. (B) Matrigel-Coated membrane assay where cells were labeled with DiIC12 fluorescent dye. (C) Matrigel-
Coated membrane assay where cells were labeled with immune-staining kit (Quik staining kit). (B and C right panel) also show quantitative data
analysis. (* = p,0.05).
doi:10.1371/journal.pone.0016068.g008
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PLoS ONE | www.plosone.org 12 January 2011 | Volume 6 | Issue 1 | e16068than 0.05 were considered statistically significant. The SPSS
software program (version 13.0, SPSS, Chicago, IL) was used for
such analyses.
Supporting Information
Figure S1 Shh signaling inhibition decreases tumorigenic
potential of NSCLC cells. (A) clonogenic growth assay of three
parental NSCLC cell lines compared to A549-M cells before and
after treatment with Hh inhibitor GDC-0449 (20 nM), and (B)
represent quantitative data analysis of the data presented in panel-
A. (* = p,0.05).
(TIFF)
Figure S2 Inactivation of Shh by cyclopamine and GDC-0449
(20 nM) led to the reduction in tumor cell invasion (A), and
tumorigenic potential (B) of H1299 NSCLC cell line. Right panel
shows quantitative analysis. (C) Western blot of H1299 cells before
and after treatment with GDC-0449 (20 nM) for the expression of
fibronectin. (D) qRT-PCR expression of E-cadherin and ZEB1
mRNA of H1299 cells after treatment with GDC-0449 (20 nM)
showing reversal of EMT compared to untreated H1299 cells.
(* = p,0.05).
(TIFF)
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